# Nephrology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Ida B. Wells (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET022-SYN
- Date: 2026-01-20
- Fictional facility: St. Posthumous Health Center
- Fictional author: Emeka Lindqvist-Moore, MD
- Calendar frame: modern shifted

- Requested by: Cordelia Ashworth-Banks, MD

## Reason for consultation

New chronic kidney disease, probably G3b A2, of uncertain cause in a 68-year-old Black woman with tiredness, ankle swelling and high blood pressure readings: race-free eGFR 40 by creatinine and 38 with cystatin C, and a urine albumin-to-creatinine ratio of 240 mg/g. Please advise on the cause and further evaluation, APOL1 genetic testing, kidney-protective treatment and its order, the anemia and mineral findings, and how and when to plan for the future. **S**

## History

Mrs. Wells, 68, is seen at the request of Dr. Ashworth-Banks for chronic kidney disease found two weeks ago. She has been tired for some months and has had ankle swelling by evening. She took naproxen for knee aching for about a year and stopped it two weeks ago. She has no diabetes, no visible blood in the urine, no foamy urine, no rash, joint swelling or mouth ulcers, and no history of kidney stones or urinary infections. She brought an outside report from two years ago: creatinine 1.05 mg/dL with an eGFR of 64 reported as normal, from an equation with a race coefficient. Her home blood pressure average over seven days is 150/88. She asked detailed questions and wants the evidence behind each recommendation. **S**

## Examination

| System | Finding |
|---|---|
| Vital signs | Blood pressure 154/90 and pulse 76, measured in clinic today |
| Cardiovascular | Regular rhythm; no rub; trace ankle swelling |
| Skin and joints | No rash; no joint swelling |

BP 154/90 mmHg; pulse 76 bpm; respirations 16/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 70 kg; BMI 28.4 kg/m². All vital signs are synthetic.

## Data reviewed

Intake results as listed by Dr. Ashworth-Banks. Recalculated earlier value: eGFR 59 by the race-free CKD-EPI 2021 equation (64 by the older race-based equation). Today's results by the older equation would read 44. Urine albumin-to-creatinine ratio 228 mg/g today (240 at intake). Urinalysis: 1+ protein, no blood, no casts; bland sediment. Serum protein electrophoresis: no monoclonal protein; free light chain ratio 1.2, normal for her eGFR. Hepatitis B surface antigen, hepatitis C antibody and HIV negative; hepatitis B surface antibody negative. Kidney ultrasound this morning: right kidney 9.6 cm, left 9.4 cm, both echogenic with thinned cortex, no hydronephrosis, stones or masses. ECG with voltage criteria for left ventricular hypertrophy. Kidney failure risk equation: about 7% at 5 years, 2% at 2 years. Urine albumin-to-creatinine ratio: 228 mg/g (high). All results are synthetic.

## Assessment

1. **Chronic kidney disease G3b A2** (N18.32). Chronic kidney disease G3b A2, present for at least two years and falling by about 10 mL/min a year. The bland urine, moderate albuminuria, small echogenic kidneys and left ventricular hypertrophy point to hypertensive kidney disease; APOL1-associated kidney disease is possible in a woman of African ancestry with this picture. There is no sign of diabetic, glomerular inflammatory or monoclonal disease, and naproxen may have added to the decline. A biopsy is not indicated now; it would be if blood appeared in the urine, albuminuria rose toward the nephrotic range, or eGFR fell quickly despite treatment. The race-free staging is correct: the older equation would have read the earlier result as normal and delayed recognition, which is the harm the NKF-ASN Task Force recommendation was written to end. Use creatinine for routine monitoring and add cystatin C when a decision depends on accuracy, such as drug dosing or transplant evaluation. **S**
2. **Hypertension with chronic kidney disease** (I12.9). Stage 2 hypertension, confirmed at home, with target organ damage. An ARB is the foundation with this albuminuria. Goal below 130/80, and a systolic below 120 by standardized measurement if she tolerates it without dizziness. **S**
3. **Anemia of chronic kidney disease** (D63.1). Mild and iron replete; no erythropoiesis-stimulating agent is indicated. Recheck in three months. **S**
4. **Vitamin D deficiency with a mildly raised PTH** (E55.9). Correct the vitamin D deficiency first; the PTH may settle. No calcitriol or phosphate binder. **S**

## Recommendations

1. Losartan 50 mg daily now, with potassium and creatinine in two weeks; accept a creatinine rise of up to 30%.
2. Then dapagliflozin 10 mg daily, which KDIGO recommends at her eGFR with albuminuria of 200 mg/g or more, with a further check at two to four weeks; then increase losartan to 100 mg if potassium stays below 5.5 mmol/L. Finerenone is not indicated without diabetes.
3. Sick-day rules in writing: hold losartan and dapagliflozin on days of vomiting, diarrhea or not eating, and before surgery or contrast.
4. No NSAIDs; acetaminophen for knee pain.
5. Atorvastatin 20 mg daily, as KDIGO advises for adults 50 or older with eGFR below 60.
6. Vitamin D3 1,000 units daily; PTH, vitamin D and hemoglobin in three months.
7. Hepatitis B vaccination, since she is not immune, with the other vaccines her primary clinician has planned.
8. APOL1 testing offered after counseling: a result would not change her medicines or blood pressure target now, may inform her risk and any future transplant evaluation, and has implications for relatives; the federal genetic nondiscrimination law does not cover life or long-term care insurance. She chose to defer, and may ask at any time.
9. Kidney education session now on the treatment options should her kidneys fail, and a dietitian session (sodium below 2 g a day, protein about 0.8 g per kg).

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Ashworth-Banks the same day. The calculations behind each eGFR, the risk estimate and the reasons for each medicine were shown to Mrs. Wells, who asked questions and agreed to start losartan and to the plan for dapagliflozin. **S**

## Follow-up

Nephrology review in three months with the urine albumin-to-creatinine ratio, then every three to six months while eGFR is below 45 and falling. Transplant evaluation and discussion of dialysis access or conservative care when eGFR approaches 20 or the 2-year kidney failure risk passes 10%, earlier if she wishes. Sooner for potassium above 5.5 mmol/L, a fall in eGFR of more than 30% after starting medicines, or blood in the urine. Dr. Ashworth-Banks continues primary care and monitoring. **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (J Am Soc Nephrol 2021)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), New England Journal of Medicine (Inker LA, et al.)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update (2017), Kidney Disease: Improving Global Outcomes (Kidney International)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
